Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-Reference-Cited by-同舟云学术

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

Published:2003-07-02 Issue:2 Volume:98 Page:229-238
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Robertson John F. R.,Osborne C. Kent,Howell Anthony,Jones Stephen E.,Mauriac Louis,Ellis Matthew,Kleeberg Ulrich R.,Come Steven E.,Vergote Ignace,Gertler Stan,Buzdar Aman,Webster Alan,Morris Charles

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

2. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

3. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

Cited by 284 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective Estrogen Receptor Degraders (SERDs);Current Breast Cancer Reports;2024-07-26

2. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway;American Journal of Physiology-Cell Physiology;2023-09-01

3. Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer;Cancer Research;2023-06-16

4. Targeted Therapy and Personalized Medicine;Therapeutic Approaches in Cancer Treatment;2023

5. Accelerating drug development in breast cancer: New frontiers for ER inhibition;Cancer Treatment Reviews;2022-09